MicroRNA-196a & MicroRNA-101 Expression in Barrett's Oesophagus in Patients with Medically and Surgically Treated Gastro-oesophageal Reflux

Overview

Journal BMC Res Notes

Publisher Biomed Central

Specialties Biology
General Medicine

Date 2011 Mar 1

PMID 21352563

Citations 2

Authors

Sebastien Haiart

David I Watson

Mary P Leong

David Astill

Tim Bright

Damian J Hussey

Affiliations

Soon will be listed here.

Abstract

Background: Proton pump inhibitor (PPI) medication and surgical fundoplication are used for the control of gastro-oesophageal reflux in patients with Barrett's oesophagus, but differ in their effectiveness for both acid and bile reflux. This might impact on the inflammatory processes that are associated with progression of Barrett's oesophagus to cancer, and this may be evident in the gene expression profile and microRNA expression pattern in Barrett's oesophagus mucosa. We hypothesised that two miRNAs with inflammatory and oncogenic roles, miR-101 and miR-196a, are differentially expressed in Barrett's oesophagus epithelium in patients with reflux treated medically vs. surgically.

Findings: Mucosal tissue was obtained at endoscopy from patients with Barrett's oesophagus whose reflux was controlled by proton pump inhibitor (PPI) therapy (n = 20) or by fundoplication (n = 19). RNA was extracted and the expression of miR-101 and miR-196a was measured using real-time reverse transcription - polymerase chain reaction. There were no significant differences in miR-101 and miR-196a expression in Barrett's oesophagus epithelium in patients treated by PPI vs. fundoplication (p = 0.768 and 0.211 respectively). Secondary analysis showed a correlation between miR-196a expression and Barrett's oesophagus segment length (p = 0.014).

Conclusion: The method of reflux treatment did not influence the expression of miR-101 and miR-196a in Barrett's oesophagus. This data does not provide support to the hypothesis that surgical treatment of reflux better prevents cancer development in Barrett's oesophagus. The association between miR-196a expression and Barrett's oesophagus length is consistent with a tumour promoting role for miR-196a in Barrett's oesophagus.

Citing Articles

OncomiR-196 promotes an invasive phenotype in oral cancer through the NME4-JNK-TIMP1-MMP signaling pathway.

Lu Y, Chang J, Liao C, Kang C, Huang S, Chen I Mol Cancer. 2014; 13:218.

PMID: 25233933 PMC: 4176851. DOI: 10.1186/1476-4598-13-218.

MicroRNA alterations in Barrett's esophagus, esophageal adenocarcinoma, and esophageal adenocarcinoma cell lines following cranberry extract treatment: Insights for chemoprevention.

Kresty L, Clarke J, Ezell K, Exum A, Howell A, Guettouche T J Carcinog. 2012; 10:34.

PMID: 22279419 PMC: 3263009. DOI: 10.4103/1477-3163.91110.

References

Bright T, Watson D, Tam W, Game P, Ackroyd R, Devitt P . Prospective randomized trial of argon plasma coagulation ablation versus endoscopic surveillance of Barrett's esophagus in patients treated with antisecretory medication. Dig Dis Sci. 2008; 54(12):2606-11. DOI: 10.1007/s10620-008-0662-7. View

Reid B, Li X, Galipeau P, Vaughan T . Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer. 2010; 10(2):87-101. PMC: 2879265. DOI: 10.1038/nrc2773. View

Shin J, Sachs G . Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008; 10(6):528-34. PMC: 2855237. DOI: 10.1007/s11894-008-0098-4. View

Luthra R, Singh R, Luthra M, Li Y, Hannah C, Romans A . MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene. 2008; 27(52):6667-78. DOI: 10.1038/onc.2008.256. View

Bright T, Watson D, Tam W, Game P, Astill D, Ackroyd R . Randomized trial of argon plasma coagulation versus endoscopic surveillance for barrett esophagus after antireflux surgery: late results. Ann Surg. 2007; 246(6):1016-20. DOI: 10.1097/SLA.0b013e318133fa85. View

Strillacci A, Griffoni C, Sansone P, Paterini P, Piazzi G, Lazzarini G . MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res. 2009; 315(8):1439-47. DOI: 10.1016/j.yexcr.2008.12.010. View

Hao Y, Triadafilopoulos G, Sahbaie P, Young H, Omary M, Lowe A . Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma. Gastroenterology. 2006; 131(3):925-33. PMC: 2575112. DOI: 10.1053/j.gastro.2006.04.026. View

Kaur B, Triadafilopoulos G . Acid- and bile-induced PGE(2) release and hyperproliferation in Barrett's esophagus are COX-2 and PKC-epsilon dependent. Am J Physiol Gastrointest Liver Physiol. 2002; 283(2):G327-34. DOI: 10.1152/ajpgi.00543.2001. View

Su H, Yang J, Xu T, Huang J, Xu L, Yuan Y . MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009; 69(3):1135-42. DOI: 10.1158/0008-5472.CAN-08-2886. View

10.

Buttar N, Wang K, Anderson M, Dierkhising R, Pacifico R, Krishnadath K . The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J Natl Cancer Inst. 2002; 94(6):422-9. DOI: 10.1093/jnci/94.6.422. View

11.

Smith C, Watson D, Michael M, Hussey D . MicroRNAs, development of Barrett's esophagus, and progression to esophageal adenocarcinoma. World J Gastroenterol. 2010; 16(5):531-7. PMC: 2816263. DOI: 10.3748/wjg.v16.i5.531. View

12.

Dijckmeester W, Wijnhoven B, Watson D, Leong M, Michael M, Mayne G . MicroRNA-143 and -205 expression in neosquamous esophageal epithelium following Argon plasma ablation of Barrett's esophagus. J Gastrointest Surg. 2009; 13(5):846-53. DOI: 10.1007/s11605-009-0799-5. View

13.

Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T . miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res. 2008; 37(Database issue):D105-10. PMC: 2686554. DOI: 10.1093/nar/gkn851. View

14.

Lagergren J, Viklund P . Is esophageal adenocarcinoma occurring late after antireflux surgery due to persistent postoperative reflux?. World J Surg. 2006; 31(3):465-9. DOI: 10.1007/s00268-006-0386-9. View

15.

Zentilin P, Conio M, Mele M, Mansi C, Pandolfo N, Dulbecco P . Comparison of the main oesophageal pathophysiological characteristics between short- and long-segment Barrett's oesophagus. Aliment Pharmacol Ther. 2002; 16(5):893-8. DOI: 10.1046/j.1365-2036.2002.01237.x. View

16.

Zaninotto G, Portale G, Parenti A, Lanza C, Costantini M, Molena D . Role of acid and bile reflux in development of specialised intestinal metaplasia in distal oesophagus. Dig Liver Dis. 2002; 34(4):251-7. DOI: 10.1016/s1590-8658(02)80144-x. View

17.

Simon P . Q-Gene: processing quantitative real-time RT-PCR data. Bioinformatics. 2003; 19(11):1439-40. DOI: 10.1093/bioinformatics/btg157. View

18.

Beck P, Mayne G, Astill D, Irvine T, Watson D, Dijckmeester W . Accuracy of identification of tissue types in endoscopic esophageal mucosal biopsies used for molecular biology studies. Clin Exp Gastroenterol. 2011; 2:1-7. PMC: 3108633. View

19.

Kuramochi H, Vallbohmer D, Uchida K, Schneider S, Hamoui N, Shimizu D . Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma. J Gastrointest Surg. 2004; 8(8):1007-16. DOI: 10.1016/j.gassur.2004.09.025. View

20.

Hofstetter W, Peters J, DeMeester T, Hagen J, Demeester S, Crookes P . Long-term outcome of antireflux surgery in patients with Barrett's esophagus. Ann Surg. 2001; 234(4):532-8; discussion 538-9. PMC: 1422076. DOI: 10.1097/00000658-200110000-00012. View